1 February 2018 · Novo Nordisk A/S
Novo Nordisk Ozempic (monthly, list)
Approved for diabetes. The other use came later.
You bought the product
$850
Launch price, Feb 2018
You bought the shares instead
$2,021
Valued 30 Jul 2026
- Return on the launch price
- 2.38×
- Annualised
- 10.7%
- Years held
- 8.5
NYSE-listed ADR. Underlying listing is Copenhagen NOVO-B.